Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives $41.25 Consensus PT from Brokerages

Assembly Biosciences, Inc. (NASDAQ:ASMB) has received an average rating of “Moderate Buy” from the seven brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $41.25.

Several equities research analysts have recently commented on the stock. JMP Securities began coverage on shares of Assembly Biosciences in a research report on Wednesday, September 24th. They set a “market outperform” rating and a $38.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Wednesday, October 8th. Citizens Jmp initiated coverage on shares of Assembly Biosciences in a research note on Wednesday, September 24th. They set an “outperform” rating and a $38.00 price target on the stock. Zacks Research raised shares of Assembly Biosciences to a “hold” rating in a research report on Tuesday, August 19th. Finally, Citigroup assumed coverage on Assembly Biosciences in a report on Wednesday, September 24th. They issued an “outperform” rating on the stock.

Assembly Biosciences Price Performance

ASMB stock opened at $36.71 on Thursday. Assembly Biosciences has a 1 year low of $7.75 and a 1 year high of $37.71. The company has a market cap of $281.64 million, a P/E ratio of -6.58 and a beta of 0.60. The stock’s fifty day moving average price is $27.37 and its 200-day moving average price is $21.48.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.22). The firm had revenue of $10.79 million for the quarter, compared to analysts’ expectations of $7.46 million. Assembly Biosciences had a negative net margin of 117.20% and a negative return on equity of 149.01%. As a group, analysts expect that Assembly Biosciences will post -6.87 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. American Century Companies Inc. purchased a new stake in Assembly Biosciences in the 1st quarter worth approximately $113,000. Acadian Asset Management LLC boosted its position in shares of Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after purchasing an additional 6,823 shares during the period. Palumbo Wealth Management LLC increased its stake in shares of Assembly Biosciences by 3.8% in the second quarter. Palumbo Wealth Management LLC now owns 18,667 shares of the biopharmaceutical company’s stock worth $338,000 after purchasing an additional 681 shares in the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of Assembly Biosciences during the 3rd quarter valued at $485,000. Finally, Ellsworth Advisors LLC purchased a new position in shares of Assembly Biosciences during the 3rd quarter valued at $852,000. 19.92% of the stock is owned by hedge funds and other institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.